Citigroup maintains Mirum Pharmaceuticals at Buy, raises price target to $194 from $184
Citigroup maintained its Buy rating on Mirum Pharmaceuticals and raised its price target to $194 from $184, implying a 105.5% upside from the Nov 10 close of $94.42. Recent analyst notes on the company have price targets ranging from $140 to $202.
How this was made
The 30-second read
Why it matters
The upgrade may trigger short‑term buying, but the long‑term outcome depends on clinical trial progress.
Market read
A fresh analyst target raise provides a modest trading signal for MIRM.
What to watch
Potential dilution from future financing rounds not reflected in the target.
Background
Analyst price target updates are a common catalyst for short‑term price moves in small‑cap biotech stocks.
Ticker impact
Citigroup raised its price target on Mirum Pharmaceuticals to $194 from $184, indicating a bullish analyst view.
likely upward pressure as investors price in the higher target
The new target represents a 5.4% increase and implies a 105.5% upside from the recent close, which may attract buying interest.
Market effects
May lift sentiment in the biotech sector as peers see higher valuation benchmarks.
Limited to U.S. markets where the stock trades.
Minimal global impact beyond biotech investors.
Counterpoint
The target raise could be premature if upcoming trial data disappoints.
Key entities
- companyMirum Pharmaceuticals
Biotech firm developing treatments for liver disease.
- analystCitigroup
Investment bank providing the rating and price target.